Understanding brain changes and social difficulties in Frontotemporal Dementia caused by GRN gene variations
Mechanisms of Thalamocortical Dysfunction and Social Deficits in FTD due to GRN Mutations
This project explores how changes in a gene called GRN lead to brain communication problems and social challenges in people with a type of Frontotemporal Dementia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11143769 on NIH RePORTER |
What this research studies
We are learning more about how a specific gene, GRN, affects brain connections and social behaviors in Frontotemporal Dementia. Our work looks at how low levels of a protein called progranulin, caused by GRN gene changes, impact important brain circuits. By understanding these brain changes, especially in areas linked to social interactions, we hope to find better ways to boost progranulin safely. This knowledge is crucial for developing new treatments that could help improve symptoms for patients.
Who could benefit from this research
Good fit: This research is relevant for patients with Frontotemporal Dementia caused by GRN gene mutations, particularly those experiencing social deficits.
Not a fit: Patients whose Frontotemporal Dementia is not linked to GRN gene mutations may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and safer treatments that target the GRN gene, potentially improving social difficulties and brain function for patients with Frontotemporal Dementia.
How similar studies have performed: Prior work has highlighted the importance of progranulin's neurotrophic effects and shown that restoring neuronal progranulin can correct FTD-related social deficits in mouse models.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Arrant, Andrew Emmett — University of Alabama at Birmingham
- Study coordinator: Arrant, Andrew Emmett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.